Ifosfamide
- Generic Name
- Ifosfamide
- Brand Names
- Ifex
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 3778-73-2
- Unique Ingredient Identifier
- UM20QQM95Y
- Background
Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.
- Indication
Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indications include treatment of osteosarcoma, bladder cancer, ovarian cancer. small cell lung cancer, and non-Hodgkin's lymphoma.
- Associated Conditions
- Bladder Cancer, Cervical Cancer, Ewing's Sarcoma, Head And Neck Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma (NHL), Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Testicular Germ Cell Cancer, Thymoma
- Associated Therapies
- -
Combination Chemotherapy in Treating Patients Undergoing Surgery for Newly Diagnosed High-Grade Osteosarcoma
- Conditions
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2011-05-16
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 60
- Registration Number
- NCT00645632
MT2004-30: Tomotherapy for Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2008-02-25
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 23
- Registration Number
- NCT00623077
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors
- Conditions
- Interventions
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 35
- Registration Number
- NCT00618813
- Locations
- 🇺🇸
Children's Oncology Group, Monrovia, California, United States
Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2015-01-14
- Target Recruit Count
- 2039
- Registration Number
- NCT00613457
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
- Conditions
- Recurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Grade III Lymphomatoid GranulomatosisRecurrent Adult Hodgkin LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Cutaneous T-cell Non-Hodgkin LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular Lymphoma
- Interventions
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2017-05-25
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 29
- Registration Number
- NCT00601718
- Locations
- 🇺🇸
Puget Sound Oncology Consortium, Seattle, Washington, United States
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
- First Posted Date
- 2008-01-18
- Last Posted Date
- 2020-08-10
- Lead Sponsor
- AIDS Malignancy Consortium
- Target Recruit Count
- 23
- Registration Number
- NCT00598169
- Locations
- 🇺🇸
Emory Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
🇺🇸UCLA Clinical AIDS Research and Education (CARE) Center, Los Angeles, California, United States
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
- Conditions
- Interventions
- Drug: cyclophosphamideDrug: cyclosporineDrug: fludarabine phosphateDrug: gemcitabine hydrochlorideDrug: ifosfamideDrug: mechlorethamine hydrochlorideDrug: melphalanDrug: methotrexateDrug: mycophenolate mofetilDrug: prednisoneDrug: procarbazine hydrochlorideDrug: vincristine sulfateDrug: vinorelbine tartrateProcedure: allogeneic bone marrow transplantationProcedure: allogeneic hematopoietic stem cell transplantationProcedure: nonmyeloablative allogeneic hematopoietic stem cell transplantationProcedure: peripheral blood stem cell transplantationProcedure: umbilical cord blood transplantationRadiation: total-body irradiation
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT00574496
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- University of Southampton
- Target Recruit Count
- 23
- Registration Number
- NCT00551122
- Locations
- 🇬🇧
Southampton General Hospital, Southampton, England, United Kingdom
🇬🇧Royal Marsden - Surrey, Sutton, England, United Kingdom
🇬🇧Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust, Birmingham, England, United Kingdom
Combination Chemotherapy and Dexrazoxane Followed by Surgery and Radiation Therapy in Treating Patients With Advanced Soft Tissue Sarcoma or Recurrent Bone Sarcoma
- Conditions
- Interventions
- Biological: filgrastimDrug: dexrazoxane hydrochlorideDrug: doxorubicin hydrochlorideDrug: ifosfamideDrug: irinotecan hydrochlorideGenetic: protein expression analysisOther: immunoenzyme techniqueProcedure: adjuvant therapyProcedure: conventional surgeryProcedure: neoadjuvant therapyRadiation: radiation therapy
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2014-08-28
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 7
- Registration Number
- NCT00544778
A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL
- Conditions
- Interventions
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2015-02-25
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 151
- Registration Number
- NCT00529503
- Locations
- 🇺🇸
Sparrow Regional Cancer Center, Lansing, Michigan, United States
🇺🇸Washington University School of Medicine, St. Louis, Missouri, United States
🇦🇺St. Vincent's Hospital, Melbourne, Fitzroy, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.